BD (BDX) announced it has completed the acquisition of Edwards Lifesciences’ (EW) Critical Care product group, which will be renamed as BD Advanced Patient Monitoring. BD Advanced Patient Monitoring will operate as a separate business unit within BD’s Medical segment to align with its smart connected care approach, and it will maintain its presence in Irvine, Calif. Katie Szyman, who has served as corporate vice president of the business under Edwards since 2015, has been named worldwide president of BD Advanced Patient Monitoring, reporting to Mike Garrison, executive vice president and president of the BD Medical segment. The completion of the acquisition is expected to have an immaterial impact to the previously disclosed BD fiscal year 2024 guidance provided in the August 1 third quarter earnings news release.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BDX:
- Becton Dickinson Announces Senior Financial Leadership Changes
- ResMed adds Becton Dickinson’s CFO Christopher DelOrefice to board
- Becton Dickinson narrows FY24 EPS view to $13.05-$13.15 from $12.95-$13.15
- Becton Dickinson reports Q3 adjusted EPS $3.50, consensus $3.31
- BD Reports Third Quarter Fiscal 2024 Financial Results